What is Sarepta Therapeutics, Inc.'s revenue?

Sarepta Therapeutics, Inc. (SRPT) generated $2.2B in revenue over the trailing twelve months, up 9.8% year over year.

Is Sarepta Therapeutics, Inc. profitable?

Sarepta Therapeutics, Inc. is not currently profitable: it reported a net loss of $579.3M over the trailing twelve months, a 4.6% net margin.

Where does Sarepta Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Sarepta Therapeutics, Inc. SRPT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$2.18B-0.6%	$2.2B—	——	——	——
Compensation and benefits	——	——	——	——	——
Depreciation and amortization	$45.14M+1.4%	$44.52M-10.5%	$49.72M+21.0%	$41.08M+5.4%	$38.96M+3.3%
Net income	——	——	——	——	-$248.39M-206%
Pre-tax stock-based compensation cost	——	——	——	——	——
Capitalized Stock Based Compensation And Depreciation As Inventory	$25.15M-1.4%	$25.51M-2.2%	$26.07M-11.6%	$29.47M-0.1%	$29.5M+3.3%
Income Taxes Paid, Net	$38.53M+2.4%	$37.63M+16.8%	$32.22M-7.1%	$34.69M+54.1%	$22.51M-0.3%
Increase (Decrease) in Accounts Receivable	-$267.05M-29.5%	-$206.25M-432%	-$38.79M-123%	$167.3M-40.4%	$280.57M+39.1%
Increase (Decrease) in Inventories	$211.97M-33.7%	$319.57M-33.6%	$481.23M+2.7%	$468.75M-8.5%	$512.02M+29.6%
Increase (Decrease) in Other Operating Assets	——	——	——	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$31.14M+109%	$14.91M+1.8%	$14.65M-2.7%	$15.06M-5.0%	$15.86M0.0%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$180.57M-7.3%	-$168.34M-110%	-$80.15M-256%	$51.4M-55.4%	$115.14M-7.7%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	——	——	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	——	——	——	——	——
Other Noncash Income (Expense)	-$5.33M+35.9%	-$8.31M—	——	——	——
Payments to Acquire Debt Securities, Available-for-Sale	——	——	——	——	$927.8M-15.6%
Payments to Acquire Intangible Assets	$6.64M-15.7%	$7.88M—	——	——	——
Payments to Acquire Property, Plant, and Equipment	$60.4M-40.8%	$101.97M-25.3%	$136.46M-9.5%	$150.79M+1.8%	$148.16M+8.2%
Proceeds from sales and redemptions of investments in debt securities classified as available for sale	$294M-0.6%	$295.87M-74.5%	$1.16B-15.4%	$1.37B-12.3%	$1.57B-21.8%
Stock-based compensation	$111.37M-9.7%	$123.4M-13.7%	$143.06M-16.6%	$171.58M-7.3%	$185.04M+0.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Sarepta Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s revenue?: Sarepta Therapeutics, Inc. (SRPT) generated $2.2B in revenue over the trailing twelve months, up 9.8% year over year.
Is Sarepta Therapeutics, Inc. profitable?: Sarepta Therapeutics, Inc. is not currently profitable: it reported a net loss of $579.3M over the trailing twelve months, a 4.6% net margin.
Where does Sarepta Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.